AOA Dx, Inc.

Based in Jersey City, New Jersey, AOA Dx, Inc. specializes in early cancer detection, focusing on women's health through advanced AI-enabled technologies that facilitate timely medical interventions. Founded in 2019 in Jersey City, New Jersey, AOA Dx, Inc. is dedicated to developing innovative solutions for cancer detection.

The company has engaged in four significant deals, with its latest funding round occurring on October 12, 2023. The most recent investment of USD 17 mn was led by Good Growth Capital, and involved participation from various investors including Astia Fund and LabCorp Ventures. AOA Dx was co-founded by Alexander Fisher, Anna Jeter, and Oriana Papin-Zoghbi, who currently serves as CEO. AOA Dx specializes in early cancer detection, particularly in women's health, using its AI-enabled platform.

The company's primary products, GlycoLocate™ and AKRIVIS GD™, utilize cutting-edge multi-omics technology to detect early-stage ovarian cancer. These diagnostic tools are aimed at healthcare providers in North America, helping them deliver timely interventions to improve patient outcomes. AOA Dx generates revenue through direct sales of its diagnostic products GlycoLocate™ and AKRIVIS GD™ to healthcare providers and diagnostic facilities. The company focuses on forming partnerships with healthcare organizations to enhance the distribution and integration of its services, ensuring that its solutions are effectively utilized in women's health screening programs.

Following its recent funding round in October 2023, which raised USD 17 mn, AOA Dx plans to advance the development of GlycoLocate™ and establish new laboratory facilities. The company aims to expand its market reach within North America, enhancing its capabilities to provide early cancer detection solutions to hospitals and diagnostic labs. The funding will support these product developments and facilitate the establishment of infrastructure to meet growing healthcare demands.